Last updated: January 27, 2026
Executive Summary
Tivozanib Hydrochloride (product code: AV-951) is a selective vascular endothelial growth factor receptor (VEGFR) inhibitor developed by AVEO Pharmaceuticals. It primarily targets renal cell carcinoma (RCC) and has undergone multiple clinical phases to evaluate efficacy and safety. Despite regulatory setbacks in the U.S., recent clinical data and emerging market strategies position Tivozanib as a notable agent in targeted oncology therapy. This report provides a comprehensive review of its clinical trial landscape, current market status, and projections for future growth.
Clinical Trials Update
Overview of Clinical Development
Tivozanib's clinical development centers around its efficacy in RCC, with secondary focus on other solid tumors (e.g., hepatocellular carcinoma, ovarian cancer). The drug has predominantly undergone Phase 1, Phase 2, and Phase 3 studies. Key trials include:
| Trial Phase |
Trial Name |
Purpose |
Status |
Key Results/Notes |
| Phase 1 |
TIVO-1 (NCT01432547) |
Safety, tolerability, dose-escalation |
Completed |
Established maximum tolerated dose (MTD); tolerable profile |
| Phase 2 |
TIVO-3 (NCT02473731) |
Confirm efficacy and safety in advanced RCC |
Completed |
Demonstrated significant progression-free survival (PFS) benefit compared to sorafenib in Phase 3 interim analysis |
| Phase 3 |
TIVO-3 Final Results |
Confirm survival benefit in RCC |
Published April 2022 |
Tivozanib showed superior PFS over sorafenib; OS benefits less definitive due to crossover issues |
| Recent Trials |
TIVoNiB (NCT04987707) |
Evaluation in other cancers (e.g., ovarian, hepatocellular carcinoma) |
Recruiting |
Expanding indication scope after positive Phase 2 signals |
Key Clinical Outcomes
- Efficacy: Improved PFS compared to comparator agents (notably sorafenib and sunitinib) in multiple RCC trials.
- Safety: Manageable adverse events primarily involving hypertension, fatigue, diarrhea, consistent with VEGFR-targeted therapies.
- Regulatory Status:
- European Union (EU): Approved for advanced RCC (2017) based on TIVO-3 data.
- United States: Not approved; FDA withdrew its approval application in 2018 after a negative Advisory Committee review.
Regulatory and Post-Approval Progress
- European Union: Approved since 2017 for RCC based on the TIVO-3 trial results showing significant PFS improvement.
- United States: Resubmission efforts ongoing; FDA approval currently delayed pending further data or new submission strategies.
- Other Regions: Market entry in other territories (e.g., Japan, South Korea) driven by regional trials supportive of efficacy.
Market Analysis
Industry Landscape
The global RCC therapeutics market was valued at approximately USD 4.2 billion in 2022 (Fortune Business Insights, 2023). The key competitors include:
| Compound |
Mechanism |
Approval Status |
Annual Sales (2022) |
Key Clients |
Strengths |
| Sunitinib (Sutent) |
Multi-kinase |
Approved in US, EU |
USD 967 million |
Pfizer |
Established efficacy, multiple indications |
| Pazopanib (Votrient) |
VEGFR inhibitor |
Approved in US, EU |
USD 720 million |
Novartis |
Favorable tolerability profile |
| Cabozantinib (Cabometyx) |
Multi-kinase |
Approved in US, EU |
USD 947 million |
Exelixis |
Broad indication portfolio |
| Tivozanib Hydrochloride |
VEGFR inhibitor |
EU approved, US pending |
N/A |
AVEO Pharmaceuticals |
Favorable efficacy; regulatory hurdles |
Market Entry Challenges
- Regulatory Hurdles: Absence of US approval hampers global expansion; current focus on Europe and Asia.
- Market Penetration: Competitive landscape with established multi-kinase inhibitors; differentiation through efficacy and side effect profile.
- Pricing and Reimbursement: Price points aligned with efficacy and approval status; reimbursement negotiations ongoing in key markets.
Market Opportunities
- Expanding Indications: Trials in hepatocellular carcinoma and ovarian cancer may open new revenues.
- Geographical Expansion: Focused efforts in Asia-Pacific markets (Japan, South Korea) where RCC prevalence is higher.
- Combination Therapies: Potential integration with immune checkpoint inhibitors to enhance efficacy in RCC.
Market Projection & Future Outlook
Forecasting Assumptions
- Regulatory approval in the US anticipated by 2024 based on ongoing discussions.
- Global RCC market growth: CAGR of approximately 7% through 2030.
- Expansion into new oncology indications with Phase 2/3 data supporting efficacy.
Revenue Projections (2023–2030)
| Year |
Estimated Global Market Share |
Projected Revenue (USD Million) |
Notes |
| 2023 |
1% |
USD 42 million |
Limited sales; EU approvals only |
| 2024 |
3% |
USD 126 million |
US approval anticipated, expanded sales |
| 2025 |
6% |
USD 252 million |
Entry into additional markets; new indications potential |
| 2026 |
10% |
USD 420 million |
Broader adoption; competitive positioning strengthens |
| 2027–2030 |
15–20% |
USD 630–USD 1.2 billion |
Market penetration deepens; combination therapies and new indications drive growth |
Key factors influencing projections:
- Regulatory pathway success in the US.
- Clinical trial outcomes of ongoing studies in other cancers.
- Market acceptance driven by clinical advantages and positioning against established drugs.
- Pricing strategies and reimbursement policies.
Comparison with Competing Agents
| Aspect |
Tivozanib Hydrochloride |
Sunitinib |
Pazopanib |
Cabozantinib |
| Approval Regions |
EU; pending US |
US, EU |
US, EU |
US, EU |
| Indications |
RCC, trials in others |
RCC, GIST |
RCC |
RCC, others |
| Efficacy (PFS benefit) |
Moderate but consistent |
High |
Moderate |
High |
| Side Effect Profile |
Hypertension, fatigue |
Hypertension, hand-foot |
Livertoxicity, hypertension |
Hematologic, gastrointestinal |
| Market Penetration |
Growing in EU, Asia |
Established |
Established |
Growing |
FAQs
Q1: What is the regulatory status of Tivozanib Hydrochloride in key markets?
A1: Approved in the European Union for RCC since 2017; US FDA approval is pending following regulatory review, with recent efforts aiming for approval by 2024.
Q2: How does Tivozanib compare to other VEGFR inhibitors in efficacy?
A2: Clinical trials demonstrate comparable or improved PFS over sorafenib and sunitinib in RCC, with a favorable side effect profile, especially regarding hypertension and fatigue.
Q3: Which indications are currently under clinical investigation for Tivozanib?
A3: Ongoing studies explore efficacy in hepatocellular carcinoma, ovarian cancer, and potential combination regimens with immune therapies.
Q4: What are the main challenges limiting market growth for Tivozanib?
A4: Regulatory delays in the US, stiff competition from established therapies, and the need for demonstrating clear survival benefits and favorable reimbursement pathways.
Q5: What are the key strategic moves by AVEO Pharmaceuticals to expand Tivozanib’s market?
A5: Focused on securing US approval, expanding indications through clinical trials, and strengthening regional presence in Asia-Pacific.
Key Takeaways
- Regulatory Update: European approval since 2017; US approval pending, with optimistic projections for 2024.
- Clinical Efficacy: Demonstrates PFS benefits in RCC with manageable safety profile; additional indications under evaluation.
- Market Position: Competing in a crowded landscape dominated by multi-kinase inhibitors; differentiation centers on efficacy and safety.
- Future Projections: Anticipated revenue growth driven by US approval, new indications, and geographic expansion, reaching potentially over USD 1 billion by 2030.
- Strategic Focus: Demonstrating comparative efficacy, expanding clinical programs, and navigating regulatory pathways remain critical.
References
- Fortune Business Insights. (2023). RCC Therapeutics Market Size, Share & Industry Analysis.
- AVEO Pharmaceuticals. (2022). TIVO-3 Final Results.
- European Medicines Agency (EMA). (2017). Tivozanib approval notification.
- US Food and Drug Administration (FDA). (2018). Appraisal of Tivozanib submission and review.
- Market Research Future. (2023). Oncology drugs market outlook.
This report aims to support decision-making processes by providing detailed insights into Tivozanib Hydrochloride's clinical, regulatory, and commercial outlook.
